The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

NCT05235737 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

DRUG: Pembrolizumab
DRUG: Pembrolizumab

Sponsor

Medical University of Silesia

Collaborators

[object Object]